Skip to main content
Propanc Biopharma, Inc. logo

Propanc Biopharma, Inc. — Investor Relations & Filings

Ticker · PPCB ISIN · US74346N4043 LEI · 549300Q3HY827FNV8Y56 US Professional, scientific and technical activities
Open in API
Filings indexed 412 across all filing types
Latest filing 2016-10-19 Regulatory Filings
Country US United States of America
Listing US PPCB

About Propanc Biopharma, Inc.

https://www.propanc.com/

Propanc Biopharma, Inc. is a clinical-stage company developing cancer treatments focused on preventing tumor recurrence and metastasis. Its lead candidate, PRP, is a pancreatic proenzyme formulation designed to target and eradicate cancer stem cells. The therapeutic approach aims to suppress tumor progression by controlling cancer cell migration, inhibiting the formation of tumor blood vessels, and inducing cell death. The company's primary focus is on developing long-term therapies for patients with solid tumors, such as pancreatic cancer.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2016
Regulatory Filings
2016-10-19 English
Regulatory Filings 2016
Regulatory Filings
2016-10-19 English
POS AM
Regulatory Filings Classification · 100% confidence The document is a Post-Effective Amendment No. 1 to a Form S-1 Registration Statement filed with the SEC. It includes references to registration of shares, a prospectus summary, risk factors, plan of distribution, and other typical sections of a registration statement for securities offering. The document is not a financial report, earnings release, or management discussion but rather a regulatory filing related to securities registration and offering. It is a filing under the Securities Act of 1933, specifically a post-effective amendment to Form S-1, which is used for registration of securities. Therefore, this document fits best under the category of Regulatory Filings (RNS), as it is a regulatory announcement and filing that does not fit into other specific report categories like Annual Report or Earnings Release.
2016-10-06 English
POS AM
Capital/Financing Update Classification · 95% confidence The document is a Post-Effective Amendment No. 1 to a Form S-1 Registration Statement filed with the SEC. It includes references to registration of shares, a prospectus summary, risk factors, and detailed information about the company and its securities offering. The document is related to securities registration and offering, not a financial report or earnings release. The Form S-1 and its amendments are filings related to securities registration under the Securities Act of 1933, which falls under capital raising activities. Therefore, this document is best classified as a Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief notice, so it is not a Report Publication Announcement or Regulatory Filing. Hence, the classification is CAP with high confidence.
2016-10-06 English
10-K
Annual Report FY 2016
2016-09-28 English
PRIMARY DOCUMENT
Director's Dealing
2016-09-27 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.